Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-02
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br CORRELATION BETWEEN CCR EXPRESSION AND CLINICOPATHOLOGIC FEATURES br

    2022-08-18


    CORRELATION BETWEEN CCR4 EXPRESSION AND CLINICOPATHOLOGIC FEATURES
    Patients with SCC were categorized into CCR4-negative (39 cases) and CCR4-positive (70 cases) groups. As presented in Table 2, CCR4-positive expres-sion was significantly correlated with tumor stage (P < .05), but there was no significant difference be-tween CCR4 Okadaic acid and other clinical parameters, such as gender, age, tobacco history, and histopatho-logic grade (Table 2).
    CORRELATION BETWEEN CCR4 EXPRESSION AND SURVIVAL OF PATIENTS WITH TSCC
    FIGURE 1. Expression of CCR4 in human tongue tumor tissues. A, CCR4 immunohistochemical staining of tongue squamous cell carcinoma and normal tongue tissues. Tongue squamous cell carcinoma tissues showed a, negative ( ), c, d, weak (+), e, f, moderate (++), and g, h, strong
    (+++) staining intensities. b, Normal tongue tissue showed very weak staining ( ). B, CCR4-positive staining was observed in other pathologic types of tongue carcinoma, including a, basal cell adenocarcinoma, b, epithelial-myoepithelial carcinoma, c, adenoid cystic carcinoma, d, mucous epidermoid carcinoma, and e, pleomorphic adenoma. Abbreviation: CCR4, chemokine (C-C motif) receptor-4.
    Wang et al. CCR4 Expression in pN0 Oral Tongue Cancer. J Oral Maxillofac Surg 2019.
    Table 1. IMMUNOHISTOCHEMICAL EXPRESSION OF CCR4
    Epithelial-myoepithelial 1 of 5 (20)
    carcinoma
    Mucous epidermoid carcinoma 2 of 4 (50)
    Abbreviation: CCR4, chemokine (C-C motif) receptor-4.
    Wang et al. CCR4 Expression in pN0 Oral Tongue Cancer. J Oral Maxillofac Surg 2019.
    Kaplan-Meier analysis and log-rank test showed that the OS and DFS of patients with CCR4-positive expres-sion were significantly lower than those of patients with CCR4-negative expression (P < .001 and P = .001; Fig 2A, B). Moreover, as CCR4 protein immu-noreactivity increased, the OS and DFS of patients with TSCC gradually decreased (Fig 2C, D).
    Table 2. EXPRESSION OF CCR4 AND ITS RELATION WITH CLINICAL FEATURES IN PATIENTS WITH TONGUE SQUAMOUS CELL CARCINOMA
    CCR4
    Gender
    Age
    Tobacco history
    Cell differentiation
    Tumor stage
    Abbreviations: , negative immunoreactivity; +, weak immu-noreactivity; ++, moderate immunoreactivity; +++, strong immunoreactivity; CCR4, chemokine (C-C motif) receptor-4.
    Wang et al. CCR4 Expression in pN0 Oral Tongue Cancer. J Oral Maxillofac Surg 2019. 
    UNIVARIATE AND MULTIVARIATE COX ANALYSES FOR PROGNOSES OF PATIENTS WITH TSCC
    To identify potential prognostic relevance, the uni-variate Cox model was applied to estimate the individ-ual clinical parameters for OS and DFS. Significant factors for OS were tumor stage (P < .001) and CCR4 expression (P = .001), and significant factors for DFS were tumor stage (P = .002) and CCR4 expression (P = .002). Then, these factors were included in the multivariate Cox model, which showed that tumor stage and CCR4 expression were independent prog-nostic factors for OS and DFS (Table 3).
    Discussion
    Local invasion and distant metastasis are the key fea-tures of primary tumors. Chemokine receptors are implicated in these processes of tumor progression.21 However, in the present study, the authors investi-gated the expression of CCR4 in patients with oral tongue cancer without lymphatic metastasis. To test the hypothesis that CCR4 is a novel prognostic biomarker for these patients, the authors detected its expression in surgically resected pN0 oral tongue can-cer specimens and investigated its correlation with clinicopathologic factors and the prognosis of patients. For the first time, the authors propose that CCR4 expression has potential as a new marker of a poor prognosis in patients with pN0 oral tongue cancer.